JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies
Tang, Yu-Long; Qi, Xing-Shun; Guo, Xiao-Zhong;
  PDF(new window)
 Abstract
Background: There is no consensus regarding the selection of treatment options for hepatocellular carcinoma (HCC) after initial transarterial chemoembolization (TACE). This meta-analysis aimed to explore the survival benefit of hepatic resection after initial TACE for the treatment of HCC. Materials and Methods: We searched three major databases to identify all relevant papers comparing the outcomes of hepatic resection after initial TACE versus TACE alone for the treatment of HCC. Hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated to evaluate the survival benefit of hepatic resection after initial TACE over TACE alone. Results: Three of 2037 initially identified papers were included. All of them were cohort studies from Asia. There was a significantly better overall survival (OS) in patients undergoing hepatic resection after initial TACE than in those undergoing TACE alone (HR
 Keywords
Hepatocellular carcinoma;transarterial chemoembolization;resection;surgery;survival;
 Language
English
 Cited by
 References
1.
Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. crossref(new window)

2.
Cao JH, Zhou J, Zhang XL, et al (2014). Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci, 34, 692-700. crossref(new window)

3.
EASL-EORTC (2012). clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 56, 908-43. crossref(new window)

4.
El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. crossref(new window)

5.
Eurvilaichit C, Kanjanapitak A (2000). Hepatocellular carcinoma : treated with hepatic arterial embolization, an analysis of prognostic features in 150 cases. J Med Assoc Thai, 83, 983-91.

6.
Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. crossref(new window)

7.
Fu QH, Zhang Q, Bai XL, et al (2014). Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 140, 1429-40. crossref(new window)

8.
Lee HS, Kim KM, Yoon JH, et al (2002). Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol, 20, 4459-65. crossref(new window)

9.
Liu L, Chen H, Wang M, et al (2014). Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One, 9, 91124. crossref(new window)

10.
Liu YM, Qin H, Wang CB, et al (2007). Comparision of different interventional therapies for primary liver cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology], 29, 232-5.

11.
Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 37, 429-42. crossref(new window)

12.
Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-9. crossref(new window)

13.
Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35, 1164-71. crossref(new window)

14.
Qi X, Liu L, Wang D, et al (2015a). Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and metaanalysis. Oncotarget, In press.

15.
Qi X, Tang Y, An D, et al (2014). Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol, 48, 450-7.

16.
Qi X, Wang D, Su C, et al (2015b). Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and metaanalysis. Oncotarget, 6, 18715-33. crossref(new window)

17.
Sieghart W, Hucke F, Pinter M, et al (2013). The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 57, 2261-73. crossref(new window)

18.
Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. crossref(new window)

19.
Wallace MC, Preen D, Jeffrey GP, et al (2015). The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol, 9, 765-79.

20.
Wang DY, Liu L, Qi XS, et al (2015). Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 16, 5573-8. crossref(new window)

21.
Wells GA, Shea B, O'Connell D, et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp.

22.
Zhang L, Hu P, Chen X, et al (2014). Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One, 9, 100305. crossref(new window)